Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Frequent epigenetic inactivation of the SLIT2 gene in gliomas

Oncogene volume 22, pages 4611–4616 (2003)Cite this article

Abstract

The SLIT family of genes consists of large extracellular matrix-secreted and membrane-associated glycoproteins. The Slits (Slit1–3) are ligands for the repulsive guidance receptors, the robo gene family. The Slit–Robo interactions mediate the repulsive cues on axons and growth cones during neural development. In a recent report, we demonstrated that promoter region CpG island of human SLIT2 was frequently hypermethylated in lung, breast and colorectal tumours and the silenced gene transcript suppressed the malignant phenotype in in vitro assays. In this report we undertook epigenetic, genetic and expression analysis of SLIT2 gene in a large series of gliomas and glioma cell lines. Promoter region CpG island of SLIT2 was found to be methylated in 71% (5/7) of glioma cell lines and was unmethylated in five DNA samples from normal brain tissues. The hypermethylation of the SLIT2 promoter region in glioma cell lines correlated with loss of expression and treatment with the demethylating agent 5-aza-2’-deoxycytidine reactivated SLIT2 gene expression. In primary gliomas, SLIT2 was methylated in 59% (37/63) of tumours analysed. In addition, SLIT2 expression was downregulated in methylated gliomas relative to unmethylated tumour samples, as demonstrated by quantitative real-time RT–PCR. Loss of heterozygosity analysis revealed that SLIT2 methylated gliomas retained both alleles of a microsatellite marker within 100 kb of the SLIT2 gene at 4p15.2. Exogenous expression of SLIT2 in a glioma cell line that was heavily methylated for SLIT2 decreased in vitro colony formation. Our data indicate that SLIT2 is frequently inactivated by promoter region CpG island hypermethylation in gliomas and may be a good candidate for a glioma tumour suppressor gene (TSG) located at 4p15.2. Furthermore, our data suggest that a detailed analysis of both the cancer genome and epigenome will be required to identify key TSGs involved in glioma development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F . (2001). Oncogene, 20, 1509–1518.

  • Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HPH, Voutilainen R, Dahia P, Eng C, Maher ER and Latif F . (2001). Oncogene, 20, 7573–7577.

  • Brose K, Bland KS, Wang KH, Arnott D, Henzel W, Goodman CS, Tessier-Lavigne M and Kidd T . (1999). Cell, 96, 795–806.

  • Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Gao B, Randle D, Virmani A, Bader S, Sekido Y, Latif F, Fong K, Gazdar AF, Lerman MI, White M and Minna JD . (2001). J. Natl. Cancer Inst., 93, 691–699.

  • Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB and Aldape KD . (2002). Cancer Res., 62, 6205–6210.

  • Costello JF and Plass C . (2001). J. Med. Genet., 38, 285–303.

  • Dallol A, Da Silva NF, Viacava P, Minna JD, Maher ER and Latif F . (2002a). Cancer Res., 62, 5874–5880.

  • Dallol A, Forgacs E, Martinez A, Sekido Y, Walker R, Kishida T, Rabbitts P, Maher ER and Latif F . (2002b). Oncogene, 21, 3020–3028.

  • Dallol A, Morton D, Maher ER and Latif F . (2003). Cancer Res., 63, 1054–1058.

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP . (2000). Nat. Genet., 25, 315–319.

  • Dammann R, Yang G and Pfeifer GP . (2001). Cancer Res., 61, 3105–3109.

  • Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li JF, Kashuba V, Klein G and Zabarovsky ER . (2001). Proc. Natl. Acad. Sci. USA, 98, 7504–7509.

  • Greger V, Debus N, Lohmann D, Hopping W, Passarge E and Horsthemke B . (1994). Hum. Genet., 94, 491–496.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM . (1994). Proc. Natl. Acad. Sci. USA, 91, 9700–9704.

  • Holland EC . (2001). Nat. Rev. Genet., 2, 120–129.

  • Jones PA . (1999). Trends Genet., 15, 34–37.

  • Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.

  • Lo KW, Kwong J, Hui ABY, Chan SYY, To KF, Chan SC, Chow LSN, Teo PML, Johnson PJ and Huang DP . (2001). Cancer Res., 61, 3877–3881.

  • Louis DN, Pomeroy SL and Cairncross JG . (2002). Cancer Cell, 1, 125–128.

  • Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW and Clifford SC . (2002). Cancer Res., 62, 5906–5911.

  • Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER . (2001). Cancer Res., 61, 7277–7281.

  • Rajagopalan S, Vivancos V, Nicolas E and Dickson BJ . (2000). Cell, 103, 1033–1045.

  • Simpson JH, Bland KS, Fetter RD and Goodman CS . (2000). Cell, 103, 1019–1032.

  • Stein E and Tessier-Lavigne M . (2001). Science, 291, 1928–1938.

  • Wong K, Ren XR, Huang YZ, Xie Y, Liu G, Saito H, Tang H, Wen L, Brady-Kalnay SM, Mei L, Wu JY, Xiong WC and Rao Y . (2001). Cell, 107, 209–221.

  • Xian J, Clark KJ, Fordham R, Pannell R, Rabbitts TH and Rabbitts PH . (2001). Proc. Natl. Acad. Sci. USA, 98, 15062–15066.

  • Yin D, Dong X, Hofmann WK, Miller CW, Black KL and Koeffler HP . (2002). Oncogene, 21, 8372–8378.

Download references

Acknowledgements

This work was in part supported by Cancer Research UK. We thank Uta Neumeister for her thorough technical assistance.

Author information

Authors and Affiliations

  1. Division of Reproductive and Child Health, Section of Medical and Molecular Genetics, University of Birmingham, Birmingham, B15 2TT, UK

    Ashraf Dallol, Luke Hesson, Eamonn R Maher & Farida Latif

  2. Department of Neurosurgery, Universitätsklinikum Carl Gustav Carus Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany

    Dietmar Krex

  3. Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, and the Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

    Charis Eng

  4. Cancer Research UK, Renal Molecular Oncology Research Group, University of Birmingham, Birmingham, B15 2TG, UK

    Eamonn R Maher & Farida Latif

Authors
  1. Ashraf Dallol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dietmar Krex
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luke Hesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charis Eng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eamonn R Maher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Farida Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farida Latif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dallol, A., Krex, D., Hesson, L. et al. Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 22, 4611–4616 (2003). https://doi.org/10.1038/sj.onc.1206687

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206687

Keywords

This article is cited by

Search

Advanced search

Quick links